Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents... Key PointsQuestionWhat is the optimal stent strategy for coronary intervention in patients with high risk for bleeding in whom a short course of dual antiplatelet therapy is preferred? FindingsIn this meta-analysis of randomized clinical trials involving 3943 patients, we found that coronary intervention with drug-eluting stents decreased the risk for myocardial infarction, target vessel revascularization, ischemia-driven target lesion revascularization, and stent thrombosis compared with bare-metal stents used with 1 month of dual antiplatelet therapy. MeaningIn patients with high bleeding risk, coronary interventions with drug-eluting stents optimized for biocompatibility appear preferable over those with bare-metal stents. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Efficacy and Safety of Drug-Eluting Stents Optimized for Biocompatibility vs Bare-Metal Stents With a Single Month of Dual Antiplatelet Therapy

Loading next page...
 
/lp/american-medical-association/efficacy-and-safety-of-drug-eluting-stents-optimized-for-N8ce3P1WmJ
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2018.3551
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat is the optimal stent strategy for coronary intervention in patients with high risk for bleeding in whom a short course of dual antiplatelet therapy is preferred? FindingsIn this meta-analysis of randomized clinical trials involving 3943 patients, we found that coronary intervention with drug-eluting stents decreased the risk for myocardial infarction, target vessel revascularization, ischemia-driven target lesion revascularization, and stent thrombosis compared with bare-metal stents used with 1 month of dual antiplatelet therapy. MeaningIn patients with high bleeding risk, coronary interventions with drug-eluting stents optimized for biocompatibility appear preferable over those with bare-metal stents.

Journal

JAMA CardiologyAmerican Medical Association

Published: Dec 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month